Thermo Fisher Scientific unveils Q digital PCR system for innovation in genetic analysis capabilities and higher research

Thermo Fisher Scientific yesterday introduced the Applied Biosystem QuantStudio Absolute Q-Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.

In a statement, Thermo Fisher Scientific said that dPCR has quickly become the standard for nucleic acid quantification in oncology, cell and gene therapy development and other research applications because its absolute quantification enables higher accuracy and precision. The company recently acquired Combinati and its cutting-edge dPCR technology to rapidly develop and commercialise it alongside an expanding portfolio of assays.

“Thermo Fisher Scientific is committed to innovation and providing the best technologies for our customers and help them accelerate innovation in areas including cancer research, rare diseases and more. QuantStudio Absolute Q Digital PCR System is a much-needed solution in biotech and research-academia space,” said Amit Chopra, Managing Director, India and South Asia, Thermo Fisher Scientific.

He added, “The device overcomes the existing challenges of precision, operation and turnaround time to provide an industry-best dPCR platform.”

Unlike complex, multi-instrument workflows required for traditional dPCR, the QuantStudio Absolute Q System uses microfluidic array technology and simplified workflows, designed to improve data accuracy and consistency. The device supports the pharmaceutical fraternity in innovating disease management, advancing significantly in generating consistent and accurate data, added the statement.

“QuantStudio Absolute Q solution is a fast and simple workflow that offers high-quality data with minimum hands-on time. It integrates all the necessary steps for dPCR—digitisation, thermal cycling, and data acquisition—into a single instrument. The dPCR is already in use for longitudinal monitoring of cancer-driving mutations in liquid biopsy and precise quantification of gene inserts for cell therapy development,” said Kapil Sood, Senior Director, Life Sciences Solutions, Thermo Fisher Scientific.